Microscale flow-through electroporation at DC voltage has advantages in delivering small molecules. Yet, electroporation based on constant voltage are liable to generate electrolysis products which limits the voltage-operating window. Parallel on-chip 3D electrodes with close and uniform spacing are required to cut down voltage as well as provide enough electric field for electroporation. Here we present a simple electrode fabrication method based on capillary restriction valves in Z-axis to achieve parallel 3D electrodes with controllable electrode spacing in PDMS chips. https://www.selleckchem.com/products/ulixertinib-bvd-523-vrt752271.html With electrodes accurately placed in close range, a low voltage of only 1.5&nbsp;V can generate enough electric field (&gt;400&nbsp;V/cm) to make cell membrane permeable. Squeeze flow is introduced to produce higher electric field (&gt;800&nbsp;V/cm) at a fixed voltage for more efficient electroporation. Benefit from the electrode fabrication method and application of squeeze flow, we develop a smartphone controlled microfluidic electroporation system which integrate functions of sample injection, pressure regulating, real-time observation and constant DC power supply. The system is used to electroporate two cell lines, showing a permeabilization percentage of 63% for HEK-293 cells and 58% for CHO-K1 cells with optimal parameters. Thus, the portable microfluidic system provides a cost-effective and user-friendly flow-through cell electroporation platform. Recently, the roles of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) were identified in polycystic ovary syndrome (PCOS). In the present study, we investigated the role of the lncRNA PVT1/miR-17-5p/PTEN axis in PCOS ovarian granulosa cells. Expression of PVT1, miR-17-5p and PTEN in PCOS ovarian granulosa cells and follicular fluid was detected, and homeostatic model assessment of insulin resistance (HOMA-IR) and the levels of fasting plasma glucose (FPG), fasting insulin (FINS), and sex hormones were assessed. Then, the proliferation, apoptosis, and colony formation ability of ovarian granulosa cells were evaluated. The binding relationship between PVT1 and miR-17-5p as well as the target relationship between miR-17-5p and PTEN were determined by bioinformatics analysis, luciferase activity assay, RNA-induced silencing complex assay, and RNA pull-down assay. The levels of sex hormone-binding globulin and follicle-stimulating hormone were abated and the levels of luteinizing hormone, testosterone, FINS, FPG, and HOMA-IR were increased in PCOS serum. PVT1 and PTEN were overexpressed and miR-17-5p was reduced in PCOS ovarian granulosa cells and follicular fluid. Overexpressed miR-17-5p and inhibited PVT1 could decelerate apoptosis while accelerating colony formation ability and proliferation of ovarian granulosa cells in PCOS. Moreover, overexpression of PVT1 and reduced miR-17-5p could reverse these results. There existed target relation among PVT1, miR-17-5p, and PTEN, and PVT1 could inhibit miR-17-5p, thereby elevating PTEN. Our study suggests that inhibited PVT1 and overexpressed miR-17-5p result in downregulation of PTEN and promotion of cell proliferation, as well as inhibition of apoptosis of ovarian granulosa cells in PCOS. AIM This pooled analysis aimed to evaluate locoregional recurrence (LRR) rates of breast cancer (BC) after neoadjuvant chemotherapy (NACT) and to identify independent LRR predictors. METHODS 10,075 women with primary BC from nine neoadjuvant trials were included. The primary outcome was the cumulative incidence rate of LRR as the first event after NACT. Distant recurrence, secondary malignancy or death were defined as competing events. For identifying LRR predictors, surgery type, pathological complete response (pCR), BC subtypes and other potential risk factors were evaluated. RESULTS Median followup was 67 months (range 0-215), overall LRR rate was 9.5%, 4.1% in pCR versus&nbsp;9.5% in non-pCR patients. Younger age, clinically positive lymph nodes, G3 tumours, non-pCR and TNBC but not surgery type were independent LRR predictors in multivariate analysis. Among BC subtypes, 5-year cumulative LRR rates were associated with higher risk in non-pCR versus pCR patients, which was significant for HR+/HER2- (5.9% vs 3.9%; HR&nbsp;=&nbsp;2.32 [95%CI 1.22-4.43]; p&nbsp;=&nbsp;0.011); HR-/HER2+ (14.8% vs 3.1%; HR&nbsp;=&nbsp;4.26 [94%CI 2.35-7.71]; p&nbsp; less then &nbsp;0.001) and TNBC (18.5% vs 4.2%; HR&nbsp;=&nbsp;4.10 [95%CI 2.88-5.82]; p&nbsp; less then &nbsp;0.001) but not for HR+/HER2+ (8.1% vs 4.8%; HR&nbsp;=&nbsp;1.56 [95%CI 0.85-2.85]; p&nbsp;=&nbsp;0.150). Within non-pCR subgroup, LRR risk was higher for HR-/HER2+ and TNBC vs HR+/HER2- (HR&nbsp;=&nbsp;2.05 [95%CI 1.54-2.73]; p&nbsp; less then &nbsp;0.001 and HR&nbsp;=&nbsp;2.77 [95%CI 2.27-3.39]; p&nbsp; less then &nbsp;0.001, respectively). CONCLUSIONS This pooled analysis demonstrated that young age, node-positive and G3 tumours, as well as TNBC, and non-pCR significantly increased the risk of LRR after NACT. Hence, there is a clear need to investigate better multimodality therapies in the post-neoadjuvant setting for high-risk patients. OBJECTIVES The study investigated the association between hospital volume and observed survival of patients with a head and neck squamous cell carcinoma (HNSCC). METHODS Overall, 9245 patients diagnosed with HNSCC between 2009 and 2014, were identified in the population-based Belgian Cancer Registry. This database was coupled with other databases providing information on diagnostic and therapeutic procedures, vital status, and comorbidities. The overall and relative survival probabilities were estimated using the Kaplan-Meier and the Ederer II methods, respectively. The relation between hospital volume and observed survival since diagnosis was then assessed using Cox proportional hazard models adjusted for potential confounders. RESULTS The care for patients with HNSCC&nbsp;in Belgium was dispersed over more than 99 centres with half of the centres treating four or less patients with HNSCC&nbsp;per year. Survival probabilities were significantly better for patients treated in higher volume centres (&gt;20 patients/year) the median survival of patients treated in these centres was 1.1 year longer (5.1 versus 4.0 years) than in lower volume centres. This association was confirmed in analyses taking the case-mix between hospitals into account the hazard to die of any cause decreased on average with 0.4% per increase of one additionally treated patient. Beyond 20 assigned patients per year, there was no further decrease in the hazard to die. CONCLUSIONS Statistically significant and clinically relevant improved survival probabilities were obtained in patients treated in higher volume centres (&gt;20 patients/year) compared with their peers treated in lower volume centres. This supports the recommendation to concentrate the care for patients with HNSCC&nbsp;in reference centres.